McKesson MCK

⚠ EARNINGS BANNER — RESULTS ARE RELEASED TOMORROW

McKesson reports first-quarter fiscal 2027 results on 2026-08-05 — ONE DAY after this dive is struck. Vendor consensus is adjusted EPS $9.56 (against $8.26 in the year-ago quarter, +15.7%) and revenue $103,875M (against $97,827M, +6.2%). The company has beaten the consensus EPS estimate in all five quarters recorded in this file — by 1.5%, 9.2%, 1.9%, 1.1% and 3.0% — and missed the revenue estimate in three of them, most recently by 5.0%.

This timing is an explicit input to the verdict, not a footnote. The Buy — Tactical rating below reflects the valuation and the separation catalyst, and it carries a hard entry discipline: no position is to be established before the print. The fiscal 2027 outlook — which the 10-K deliberately does not reproduce, stating only that it "is contained in the release of our fourth quarter fiscal 2026 financial results included as an exhibit to our Form 8-K furnished to the SEC on May 7, 2026, which is not incorporated by reference" — is the anchor for the FY2027 consensus of $44.26 on which every fair value in this dive rests. If tomorrow's guidance moves that number materially, the fair values move with it and this document is superseded.

Reference table

1. What the business is — and it was reorganised this year

McKesson is a Delaware-incorporated healthcare services company with approximately 43,000 employees, Brian S. Tyler as chief executive, and fiscal years ending 31 March. Fiscal 2026 ended 2026-03-31.

The segment structure CHANGED in fiscal 2026, and the payload's historical years are not recast. The company now reports four segments plus Corporate; the prior structure had U.S. Pharmaceutical and International.

Fiscal 2026 revenue by segment, from seg_prod — and this block RECONCILES EXACTLY, which is worth recording:

The seg_prod block sums to the reported revenue line to the dollar, in both fiscal 2026 and fiscal 2025 (FY2025: $14,721M + $11,386M + $5,216M + $327,717M = $359,040M against a reported $359,051M, an $11M or 0.003% difference). After the seg_prod failures documented across this programme — MDT's 147% geography, SPGI's missing $2,299M segment, HWM losing two segments in consecutive years — a block that reconciles exactly in two consecutive years deserves to be recorded as clean, and it is. The limitation is different: the two years are on different structures and were not recast, so no year-over-year segment comparison can be drawn from the payload. Comparing "U.S. Pharmaceutical $327,717M" in FY2025 against "North American Pharmaceutical $336,652M" in FY2026 is comparing two different definitions.

Foreign operations were approximately 4% of consolidated revenue in each of fiscal 2026 and fiscal 2025, per the 10-K — down from 16.6% in fiscal 2020 as the European and Canadian retail businesses were sold.

The Medical-Surgical separation — three filings, one transaction, none of it in the payload

This is the largest thing happening at McKesson and the vendor data contains no trace of it.

From the 10-K (filed 2026-05-08):

> "During fiscal 2026, we announced our intention to separate this segment into an independent company. As a part of the separation strategy, on April 20, 2026, we announced a definitive agreement under which funds managed by affiliates of Apollo Global Management, Inc. ('Apollo Funds') will acquire approximately 13% minority ownership interest in our Medical‑Surgical Solutions segment through an investment of approximately $1.25 billion in the segment's convertible preferred equity. This transaction is subject to regulatory approvals and customary closing conditions."

And from the risk factors, in the company's own words:

> "The Company intends to separate the Medical-Surgical Solutions segment into an independent company ('NewCo'). The separation is expected to be effected, ultimately, through a split-off or spin-off, or a combination of both (the 'Exit'), intended to qualify as a tax-free transaction... Completion of the planned separation will be subject to the satisfaction of various conditions, including... the receipt of a favorable opinion from outside legal counsel as to the tax-free nature of the Exit; the effectiveness of a registration statement to be filed with the SEC; the receipt of other governmental approvals; the finalization of the NewCo capital structure; and the approval of our Board of Directors. The planned separation is complex in nature..."

Then, from the 8-K filed 2026-06-12 — the capital structure being finalised in public:

> "On June 9, 2026, certain of McKesson Corporation's... subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the 'Borrower'), entered into an amendment... to the Credit Agreement, dated as of April 1, 2026... to provide for a $2,250.0 million senior secured term 'B' loan facility due 2032... at the Adjusted Term SOFR Rate... plus an applicable margin equal to 2.25% per annum... All of the Borrower's obligations under the Credit Agreement are secured... by a security interest in substantially all tangible and intangible assets of the Borrower and each of the Borrower's certain material U.S. subsidiaries... the Borrower will be subject to financial covenants... (i) a maximum total net leverage ratio covenant and (ii) a minimum interest coverage ratio covenant."

Read the three together and the sequence is unambiguous. A separate holding company was created for Medical-Surgical (credit agreement dated 1 April 2026), a financial sponsor was signed to validate the price and take 13% (20 April), and $2.25 billion of secured leveraged-loan financing was placed into it (9 June). That is a segment being levered and prepared for exit, and the proceeds are the reason it matters to a McKesson shareholder.

The arithmetic, stated as arithmetic. Medical-Surgical had $11,507M of fiscal 2026 revenue, roughly 2.9% of the total, and the 10-K describes its operating profit as helped by "lower restructuring charges" and "business rationalisation initiatives" and hurt by "$25 million charges related to our planned separation" and "a decline in the contribution from our ambulatory care business." Apollo's ~$1.25 billion for ~13% implies a headline equity value near $9.6 billion for the segment before the $2.25 billion of new debt — we present that as the implied arithmetic of the disclosed terms and nothing more, since convertible preferred is not common equity and the disclosed figures are approximations. What is not in doubt: McKesson is separating roughly 3% of its revenue and will receive cash for it, from a business whose growth and margin profile is the weakest of the four.

None of this appears in the vendor payload. bal_a ends 2026-03-31, before the Term B loan; cf_a ends fiscal 2026; there is no pro-forma anywhere. A screen run on this file is looking at a company that has not announced anything.

The two acquisitions that built Oncology & Multispecialty

From the 10-K: "Investing activities for the March 31, 2026 included $3.4 billion of net cash payments for acquisitions, including $2.5 billion and $875 million for the acquisitions of the interests in Core Ventures and PRISM Vision, respectively." PRISM Vision is held at an 80% controlling interest; Sarah Cannon Research Institute at 51%. That is where the noncontrolling interest on the balance sheet came from — $380M at 2025-03-31 becoming $1,338M at 2026-03-31, a 252% increase. It is also why the vendor's enterprise value is understated; see Section 8.

2. The economics — why a 1.18% net margin earns 31% on capital

Every figure in this business must be read against its margin structure, which is the thinnest of any name in this batch:

The reconciliation between a 1.18% margin and a 31% return is the working-capital cycle, and it is the whole business model:

McKesson is paid by its customers eight days before it pays its suppliers. Working capital is negative $9,807 million — that is, the business is funded by its own trade payables, and $403 billion of annual revenue requires no net capital at all. Growth therefore generates cash rather than consuming it, which is why a company with a 1.18% net margin can return 5.3% of its market capitalisation to shareholders every year.

The vulnerability of the model is the same fact seen from the other side. A working-capital cycle that funds the business is a cycle that reverses violently if trade terms move. The 10-K's own explanation of the fiscal 2026 cash flow shows the sensitivity: an "increase in net cash of $1.9 billion related to accounts receivable" offset by a "decrease in net cash of $4.0 billion related to accounts payable as a result of customary vendor payment scheduling, timing related to the day of the week on which the period ends, and the impact from branded pharmaceutical price decreases." A single change in the day of the week on which the fiscal year ends moves billions of dollars through this company's cash flow. Operating cash flow of $6.2 billion should be read as a multi-year average, not a quarterly signal.

3. The earnings trajectory

GAAP diluted EPS for FY2026 and FY2025 is the 10-K's figure ($38.38 and $25.72). The vendor's inc_a.eps reads 38.55 and 25.86 — a 0.4% and 0.5% overstatement, being the basic rather than diluted measure. The filing wins and we use $38.38. Adjusted EPS is the sum of the four earn_cal quarterly actuals, which is the basis every forward estimate in the file uses.

The quarterly record, and it is unusually consistent on earnings and unreliable on revenue:

Five consecutive earnings beats and three revenue misses, one of them 5.0%. On a 1.18% net margin, revenue is close to an irrelevant variable — a 5% revenue miss with a 1.1% earnings beat is exactly what you would expect from a business whose profit is a spread and a fee rather than a percentage of the invoice. The 10-K names the cause: branded pharmaceutical price decreases, which shrink the dollars flowing through without touching the economics. We treat revenue estimates for this name as non-informative and grade the company on earnings and cash flow.

Fiscal 2026's profit drivers, from the 10-K's segment commentary:

• North American Pharmaceutical: higher volumes, a LIFO credit of $210 million (against a charge in the prior year), and the absence of the prior year's $57 million opioid charge and Canadian retail remeasurement — partially offset by lower antitrust settlement proceeds and the prior-year Rite Aid bankruptcy effect.
• Oncology & Multispecialty: "growth in specialty pharmaceuticals, including contributions from FY26 business acquisitions," a $51 million net gain on an investment sale, and the absence of a prior-year $43 million equity-method loss.
• Prescription Technology Solutions: "higher demand for access solutions."
• Medical-Surgical: lower restructuring, business rationalisation — offset by $25 million of separation charges and "a decline in the contribution from our ambulatory care business."
• Corporate: higher restructuring, a $52 million separation charge, Norway disposal charges, against a prior-year $87 million UK pension termination charge.

Note how much of the year-on-year improvement is the absence of prior-year charges rather than the presence of current-year growth. The Rite Aid bankruptcy alone cost $725 million of bad-debt provision in fiscal 2024 and produced $483 million of releases in fiscal 2026. The underlying operating improvement is real but smaller than the reported 49% GAAP EPS increase suggests, and the adjusted series — $39.15 against roughly $33.10, or 18% — is the better read.

4. Balance sheet, capital structure and the negative equity

The negative equity is a buyback artefact and must be labelled as such rather than as distress. McKesson has repurchased $4,750M, $3,146M, $3,025M and $3,638M of stock in the last four fiscal years — $14.6 billion against a company whose retained earnings are $22,291M — and treasury stock is carried as a reduction of equity. The business generates $6.2 billion of operating cash flow a year and carries net debt of 0.66x EBITDA. It is not levered; it is simply not equity-financed.

But the consequence for the data file is total. priceToBookRatioTTM reads −46.68x, returnOnEquityTTM reads −2.654 (−265%), debtToEquityRatioTTM reads −3.97x, financialLeverageRatioTTM reads −37.90x, tangibleBookValuePerShareTTM reads −$132.92, and bookValuePerShareTTM reads −$6.83. Every one of these is arithmetically correct and analytically void. The vendor's own composite rating scores McKesson 1 out of 5 on return on equity, 1 out of 5 on debt-to-equity and 1 out of 5 on price-to-book, producing an overall B− / 2 for a company earning 31.1% on invested capital. The rating block is rejected for this name in its entirety.

The measures that do apply: return on invested capital 31.07%, return on capital employed 41.62%, net debt to EBITDA 0.66x, interest coverage 51.0x, and free cash flow.

Debt actions in fiscal 2026 and after, from the 10-K: a public offering completed 2025-05-30 of 4.65% Notes due 2030 ($650M), 4.95% Notes due 2032 ($650M) and 5.25% Notes due 2035 ($700M) for $2.0 billion net, used to fund the Core Ventures purchase; €600M of 1.50% Notes matured 2025-11-14 and $500M of 0.90% Notes matured 2025-12-03, both repaid from cash. In April 2026 the $4.0 billion revolver and $1.0 billion 364-day facility were terminated and replaced with a new $5.0 billion revolving credit facility maturing April 2031. And on 2026-06-09 the $2,250 million secured Term B loan was added at the Medical-Surgical holdco — which, if it remains at NewCo through the separation, leaves McKesson's own leverage unchanged and if it does not, adds roughly 0.3x to net leverage. Pro-forma for the Term B alone, net debt is approximately $6,889M, still under 1.0x EBITDA.

Capital return, and it is the second-largest component of the expected return:

$4.8 billion of repurchase in one year is 4.9% of the current $97.2 billion market capitalisation. The dividend at $3.28 per share is a 0.40% yield and a 8.0% payout ratio — this company returns capital almost entirely through buyback. Total shareholder yield is approximately 5.3%, and on a 124-million share count it is worth roughly four points of annual EPS growth on its own.

5. Customer concentration — the risk that is not diversifiable

From the 10-K, and it is stated more plainly than most companies would:

> "Sales to our ten largest customers, including group purchasing organizations ('GPOs'), accounted for approximately 73% of total consolidated revenues in fiscal 2026 and comprised approximately 43% of total trade accounts receivable at March 31, 2026. Sales to our largest customer, CVS Health Corporation ('CVS'), accounted for approximately 24% of our total consolidated revenues in fiscal 2026 and comprised approximately 21% of total trade accounts receivable at March 31, 2026. Sales to our next two largest customers accounted for 11% and 10% of total consolidated revenues."

This is the single biggest risk in the file and there is no mitigation available to a shareholder. Nearly a quarter of revenue depends on one contract with one company. The offsetting realities, stated fairly: distribution contracts of this size are multi-year and switching costs are enormous; the three-firm structure of US drug distribution means the alternatives are two competitors, both of whom would price the business aggressively; and the profit share of any individual customer is far below its revenue share, because large-volume contracts carry the thinnest spreads. The receivables data supports that: CVS is 24% of revenue and 21% of receivables, so it is not being financed on unusual terms.

The precedent for what customer failure costs is in this same filing. Rite Aid's October 2023 bankruptcy produced a $725 million bad-debt charge in fiscal 2024 within North American Pharmaceutical — against a customer far smaller than CVS. Fiscal 2026's provision for bad debts was a $100 million charge; fiscal 2025's was a $130 million CREDIT; fiscal 2024's was an $819 million charge. The allowance is now 0.8% of $24.5 billion of trade and notes receivable, down from 2.1%.

The other permanent risk is opioid litigation. Fiscal 2026 carried a $108 million charge for estimated opioid-related claims (fiscal 2025: $57 million); the company operates under consent decrees issued by state courts governing its distribution of controlled substances; and the 10-K notes that certain states have enacted and others are considering "legislation that would impose taxes, assessments, or similar charges on the distribution of controlled substances." At roughly $100 million a year against $6.2 billion of operating cash flow this is currently a nuisance rather than a threat, and it is priced as one. It has not always been.

6. Valuation — priced in or room?

At $830.43 (market capitalisation $97.23B, implied 117.08M shares):

Estimate coverage is adequate on the two years that matter and collapses beyond. Nine analysts on FY2027 and FY2028 adjusted EPS; three on FY2029; and ONE analyst each on FY2030 ($66.97) and FY2031 ($79.01). The FY2030 and FY2031 rows are single-analyst extrapolations and are excluded from every conclusion in this dive — they are reported here only so that nobody mistakes the payload's eight-year estimate array for eight years of consensus. The FY2027 EPS range is $44.07 to $44.48, a 0.9% spread across nine analysts, which is extraordinarily tight and tells you the street is modelling company guidance rather than forming independent views.

est.ebitdaAvg and est.ebitAvg are rejected outright for the fixed-ratio fabrication signature. In FY2026, FY2027, FY2028 and FY2029 alike, ebitdaAvg is exactly 1.6003% of revenueAvg and ebitAvg is exactly 1.3499%. Four consecutive years at five-decimal precision is not a forecast. All forward valuation uses epsAvg, cross-checked against the five earn_cal actuals.

Enterprise value is usable here — unlike the bank in this batch — but it needs the noncontrolling-interest correction. The vendor prints enterpriseValueTTM of $101,864M = market capitalisation $97,225M + net debt $4,639M. It omits the $1,338M of noncontrolling interests arising from the 80% PRISM Vision and 51% Sarah Cannon holdings. Corrected enterprise value is $103,202M, 1.3% higher, and EV/EBITDA moves from the vendor's 14.52x to 14.7x. This is the SPGI defect class — there the omission was 3.9% — and it is small here but it is the same error and it is recorded. Finance lease obligations of $2,240M ARE included in totalDebt, correctly; there is no lease double-count of the T or TJX class.

Peer context is poor. The vendor set is Bristol-Myers Squibb, Cardinal Health, Cencora, CVS Health, GSK, HCA, Medtronic, Sanofi, Stryker and Vertex. Only two of the ten — Cardinal Health ($54.7B) and Cencora ($59.6B) — are drug distributors, and they are the only valid comparison. Four are branded pharmaceutical manufacturers, two are medical-device makers, one is a hospital operator and one is McKesson's own largest customer. We draw no peer multiple from this set beyond noting that MCK at $97.2B is larger than Cardinal Health and Cencora combined, and that the knowledge base's one relevant claim explicitly pairs McKesson with Cardinal Health.

6a. What today's price assumes (the inversion)

At $830.43 — 18.8x FY2027 consensus adjusted EPS, 16.5x FY2028, 14.7x EV/EBITDA — the price embeds:

• Adjusted EPS reaches $44.26 in FY2027 and $50.42 in FY2028. (Consensus; 9 analysts each, with an FY2027 range of only 0.9%.) That requires 13.1% then 13.9% growth against fiscal 2026's actual $39.15. The first data point arrives TOMORROW against a $9.56 estimate.
• The buyback continues near $4.8 billion a year. (Our number, from the fiscal 2026 cash flow statement.) At 4.9% of market capitalisation annually, it contributes roughly four points of the thirteen points of expected EPS growth. If cash is redirected to the separation or to acquisitions, roughly a third of the earnings growth disappears without any change in the operating business.
• CVS remains a customer on approximately current terms through FY2028. (Filing-disclosed 24% concentration; our extrapolation.) This is the most fragile assumption in the price — not because a loss is likely, but because it is the only single event that could remove a quarter of the revenue base, and the price contains no discount for it whatsoever.
• The Medical-Surgical separation completes without value leakage. (Our number.) The market is paying 18.8x for a consolidated entity in which the segment being removed is 2.9% of revenue and the weakest of the four. The price appears to embed neither a separation premium nor a failure discount — it looks to us as though the transaction is simply not in the number.
• The market keeps paying roughly 18-21x forward earnings. (Our number.) At 16x FY2027E the stock is $708; at 22x it is $974. McKesson traded near 11x forward earnings as recently as 2023 on the knowledge base's own account, so the multiple band this business has occupied is very wide and the current level is mid-to-upper.

6b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+13.1%, from FY2026 actual $39.15 to FY2027E $44.26) + multiple drift (roughly HELD to mildly expanded, 18.8x on the forward year moving to about 19.5x on the then-forward year, +3 to +4%) + shareholder yield (+5.3%, almost entirely buyback) ≈ +12% to +15%.

Our base assumes the multiple essentially holds, with a small allowance for the separation. That allowance is the one piece of judgment in the number and we flag it as such. The argument for expansion is that a post-separation McKesson is 97% pharmaceutical distribution, oncology services and access technology, without the drag of a restructuring-heavy medical-supplies business, and that such a company deserves more than 18.8x. The argument against is that 83.4% of the remainder is still a 1.18%-net-margin logistics business and no reorganisation changes that.

Note the composition of the return: roughly two-thirds earnings growth, roughly a third shareholder yield, and very little from the multiple. That is a robust decomposition — the base case does not require the crowd to change its mind, which is the same structural quality that earned Capital One the Tactical tier in this batch.

If the multiple compressed to 16x FY2027E the price is $708 (−14.7%). If it expanded to 22x, $974 (+17.3%). The bull case at $1,090 is 24.5x the FY2027 consensus high of $44.48 — a level that requires the separation to complete on good terms AND the specialty mix shift to be recognised.

6c. Variant perception (where we differ, what would surprise)

• We are 7.6% BELOW the street and that is the deliberate variant. Our $930 against a consensus $1,006, a median $1,050 and a low target of $875 that is itself above spot. Thirty-one analysts, 25 at buy or better, none at sell, and the most bearish of them sees 5.4% of upside. When no covering analyst sees downside in a company with 24% single-customer concentration, negative book equity and a complex separation in flight, the appropriate response is to sit below the distribution rather than in it. That is where our number is and why.
• We think the Medical-Surgical separation is not in the price and the market has not been given enough to put it there. Three filings across ten weeks describe a segment being given its own holding company, its own $2.25 billion secured credit facility with leverage covenants, and a 13% financial-sponsor shareholder — and the segment is 2.9% of revenue, so no screen will flag it. Watchable event: confirmation on the 2026-08-05 call of the separation timetable and the Apollo Funds closing. A named date and a cleared regulatory approval would be the first hard evidence, and it would be positive.
• We think the revenue line on this name should be ignored and the market keeps reacting to it. The March quarter missed the revenue estimate by 5.0% while beating on earnings by 1.1%. On a 1.18% net margin, a 5% revenue variance driven by branded price deflation is nearly irrelevant to profit. Watchable number: whether the 2026-08-05 print misses revenue again against $103,875M while beating the $9.56 EPS estimate. If it does and the stock falls, that is the entry.
• Positive surprise that would force a re-rate: the Oncology & Multispecialty segment being given separate revenue AND operating-profit disclosure with growth rates attached — it is $48.4 billion of revenue containing a physician network, 51% of a clinical research organisation and 80% of an ophthalmology platform, and it is currently a single line. Or a separation announcement with a date, a structure and a use of proceeds.
• Negative surprise that would break the thesis: any disclosure touching the CVS relationship; a fiscal 2027 outlook below the $44.26 consensus at tomorrow's print; the Apollo Funds transaction failing regulatory approval, which would strand the separation and leave $2.25 billion of secured debt at a subsidiary with nowhere to go; a return of opioid charges to a nine-figure quarterly level; or a bad-debt event at another large customer of the Rite Aid class.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $44.26, low $44.07, high $44.48, 9 analysts), each cross-checked against FY2028.

• Bear ~$700 — 15.9x the FY2027 consensus LOW of $44.07, cross-checked at 13.9x FY2028E. The scenario: the fiscal 2027 outlook disappoints tomorrow, the separation stalls on regulatory approval leaving $2.25 billion of secured subsidiary debt in place, a large-customer credit event or contract renegotiation appears, and the multiple returns toward the low end of the range this business has occupied. 6.2% above the 52-week low of $659.01. −15.7%.
• Base ~$930 — 21.0x the FY2027 consensus MEAN of $44.26, cross-checked at 18.4x FY2028E and 16.1x FY2029E. Sensitivity, stated openly: 19x gives $841, essentially spot; 23x gives $1,018. The answer lives inside a 19-23x band on one estimate row that only nine analysts contribute to. The scenario: 13% earnings growth delivers, the buyback continues near $4.8 billion, the separation completes without value leakage, and the multiple holds with a small allowance for the cleaner remainder. +12.0%.
• Bull ~$1,090 — 24.5x the FY2027 consensus HIGH of $44.48, cross-checked at 21.6x FY2028E. 9.5% above the 52-week high of $995.69. The scenario: the separation completes with disclosed proceeds, Oncology & Multispecialty is broken out and grows at a visibly higher rate than the group, and the market begins valuing McKesson partly as a specialty-care services platform rather than wholly as a distributor. +31.3%.

Base is 12.0% above spot; asymmetry roughly 2.0:1 to the upside (15.7% down, 31.3% up), before a shareholder yield of approximately 5.3%. A base above 12%, a payoff ratio of 2:1, a return that is two-thirds earnings growth, and an entry 16.6% below the 52-week high is what the Buy — Tactical tier exists for. What it is NOT is a reason to buy the day before a print, and Section 11 says so.

7. Knowledge base — three claims, one voice, and the concentration test fails

Raw hits: 3. Entity matches: 3. Used: 3. Discarded: 0. Distinct voices: ONE.

The sweep ran case-sensitive entity tokens MCK and McKesson, plus case-sensitive free-text patterns for both, across all 51,928 distilled claims. It returned three claims. Every one is from the channel jordi_visser. Every one is bullish. Every one carries skill weight 2.0 — the highest in the store.

> 2025-03-30 · bullish · conviction 70 · skill 2.0 · horizon: thesis · entities: MCK, CAH · categories: healthcare · channel: jordi_visser · speaker: null · speaker_role: independent

> "McKesson and Cardinal Health trade below market multiple yet keep producing significant price returns; as momentum names they haven't unwound because they make money and are reasonably priced."

> 2025-11-16 · bullish · conviction 68 · skill 2.0 · horizon: thesis · entities: MCK · categories: healthcare, AI margins · channel: jordi_visser · speaker: null · speaker_role: independent

> "McKesson is a beast, up another 50% this year, gone from 11 PE to 22 on profit margins from companies able to use AI."

> 2025-11-16 · bullish · conviction 60 · skill 2.0 · horizon: thesis · entities: MCK · categories: healthcare, AI beneficiary, margins · channel: jordi_visser · speaker: null · speaker_role: independent

> "McKesson is a beast on profit margins — gone from an 11 PE to 22 using AI; expect more names like this as fundamental funds hunt AI-margin beneficiaries."

The concentration test, run because one channel supplies more than a third of the lane, and failed comprehensively. One channel supplies 100%. Removing jordi_visser empties the lane entirely. There is therefore no independent corroboration in this knowledge base for any view on McKesson — there is one person's opinion, recorded three times, twice on the same day in slightly different words. We weight it accordingly: the lane is scored breadth 1, claim count 3, net conviction positive-low, and it contributes very little to the verdict.

Attribution note, applying the house policy. All three claims carry speaker: null and are attributed only to a channel — the weakest sourcing the four-lane policy admits — while carrying speaker_role: independent. Per the standing finding that speaker_role is unreliable (it failed for Glenn Fogel, Albert Bourla and a nine-claim Andrew McDonald block), we do not rely on that tag. We judge the content instead: the claims read as an independent investor's market commentary, not as company guidance, and there is no indication of a commercial relationship with McKesson. They are admitted to the conviction pool at low weight for concentration, not excluded.

Grading them, which is the part that matters. The March 2025 claim — that McKesson and Cardinal Health trade below the market multiple while producing significant price returns — was right: the stock rose materially through 2025 to a 52-week high of $995.69. The November 2025 claims are the more specific and they have not worked since. The stock is down 1.9% over the trailing six months while the S&P rose 11.1%, and the multiple has gone the other way — from the 22x he described to 21.2x trailing and 18.8x forward. The most recent, most confident and highest-skill claim in this lane has stalled, and we report it as stalled rather than as pending.

One substantive observation the lane does contribute. The AI-margin framing — that McKesson's re-rating from 11x to 22x reflected margin expansion at "companies able to use AI" — is an interpretation, not a fact, and nothing in the 10-K attributes any margin improvement to artificial intelligence. The filing attributes fiscal 2026's operating profit growth to volumes, a $210 million LIFO credit, the absence of prior-year charges, and acquisition contributions. Where a knowledge-base claim and a filing offer competing explanations for the same number, the filing wins, and it does here.

Homograph check — run and clean. "MCK" is a three-letter ticker with collision potential, but the case-sensitive word-boundary sweep produced no false positives, and "McKesson" is unambiguous. No claims were discarded, which is unusual and is recorded.

8. Data integrity — what we rejected and why

Eight findings. Two of them are material to the cash-flow arithmetic, one voids an entire class of ratios, and one block passed a test that has failed on most names in this programme.

1. capitalExpenditure omits capitalised software for fiscal 2026 — and got fiscal 2025 RIGHT, so the block is internally inconsistent. The 10-K states: "Investing activities for the year ended March 31, 2026 included $436 million and $309 million, respectively, in capital expenditures for property, plant, and equipment and capitalized software." Total fiscal 2026 capital expenditure is $745 million. The vendor reports $436 million — a 41% understatement. For fiscal 2025 the 10-K states "$537 million and $322 million" — total $859 million — and the vendor reports exactly $859 million. So the same field is built on two different definitions in consecutive years. Consequences: vendor free cash flow of $5,719M for fiscal 2026 should be $5,410M; freeCashFlowYieldTTM of 6.11% should be 5.56%; capexToDepreciationTTM of 0.569 should be 1.022; capexToRevenueTTM of 0.054% should be 0.185%. This is the COP defect class in a milder form — there capex was 76% understated and turned a 5.04% FCF yield into 10.71% — and the sanity check that caught it is the same one: capex of $436M against D&A of $729M is implausibly low for a company operating a continental distribution network, and the filing settles it. We use $745 million and $5,410 million throughout.

2. acquisitionsNet understates fiscal 2026 acquisition spend by roughly $800 million. The vendor reports −$2,586M. The 10-K states: "Investing activities for the March 31, 2026 included $3.4 billion of net cash payments for acquisitions, including $2.5 billion and $875 million for the acquisitions of the interests in Core Ventures and PRISM Vision, respectively." $2.5B + $875M alone is $3,375M against the vendor's $2,586M. The filing wins.

3. Stockholders' equity is negative, so an entire class of ratios is arithmetically correct and analytically void — REJECTED as a class. Total stockholders' equity is −$2,172M at 2026-03-31. Consequently: priceToBookRatioTTM −46.68x, priceToFairValueTTM −46.68x, returnOnEquityTTM −2.654 (−265%), debtToEquityRatioTTM −3.97x, debtToCapitalRatioTTM 1.337, longTermDebtToCapitalRatioTTM 1.740, financialLeverageRatioTTM −37.90x, bookValuePerShareTTM −$6.83, tangibleBookValuePerShareTTM −$132.92, shareholdersEquityPerShareTTM −$17.79, grahamNumberTTM null, grahamNetNetTTM −$377.48, solvencyRatioTTM 0.066. None is used anywhere in this dive. The measures used are ROIC (31.07%), ROCE (41.62%), net debt to EBITDA (0.66x) and the cash conversion cycle (−8.25 days).

4. The vendor composite rating is rejected in its entirety as a direct consequence of finding 3. rating gives B− / 2 overall, with 1 out of 5 on return on equity, 1 out of 5 on debt-to-equity and 1 out of 5 on price-to-book — three scores that are mechanically driven by the negative equity described above — against 5 out of 5 on discounted cash flow, which is built on the free-cash-flow figure corrected in finding 1. A composite rating of 2 out of 5 on a company earning 31.1% on invested capital is a measurement artefact, and treating it as a signal would invert the conclusion.

5. enterpriseValueTTM omits $1,338M of noncontrolling interests — the SPGI defect class, smaller. The vendor computes EV as market capitalisation $97,225M plus net debt $4,639M = $101,864M, ignoring the NCI arising from the 80% PRISM Vision and 51% Sarah Cannon holdings. Corrected EV is $103,202M, 1.3% higher, moving EV/EBITDA from 14.52x to 14.7x and EV/sales from 0.2525x to 0.2559x. Note that NCI grew 252% during fiscal 2026 (from $380M to $1,338M) as those interests were acquired, so this omission is getting worse, not better. We use the corrected figure.

6. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. ebitdaAvg is exactly 1.6003% of revenueAvg and ebitAvg exactly 1.3499% in FY2026, FY2027, FY2028 and FY2029. Four consecutive years to five decimal places. All forward valuation uses epsAvg, which is independently validated: the FY2026 estimate of $39.011 against an actual $39.15 (the sum of four earn_cal quarterly actuals) is a 0.4% difference.

7. inc_a.eps is the basic rather than diluted measure and overstates the filing's figure. The vendor reports FY2026 eps of 38.55 and FY2025 of 25.86; the 10-K states "Diluted earnings per common share attributable to McKesson Corporation was $38.38 and $25.72." Overstatements of 0.44% and 0.54%. The filing wins and we use $38.38. Note the vendor's weightedAverageShsOutDil of 124.1M and 128.1M match the 10-K exactly, so the share counts are right and only the per-share line is on the wrong basis.

8. seg_geo stops at fiscal 2020 and using it would be badly wrong — REJECTED. The most recent entry is FY2020: International Segment $38,342M, United States $192,709M — implying 16.6% international. The 10-K states that foreign operations were approximately 4% of consolidated revenue in each of fiscal 2026 and fiscal 2025. The gap is six years of divestitures (European operations, Canadian retail, Norway). A screen using this block would model McKesson as four times more internationally exposed than it is. The block is not used; the 10-K's 4% is.

seg_prod — TESTED AND PASSED, which is worth as much as the failures. The fiscal 2026 entry sums to $403,430M against a reported revenue of $403,430M — exact. The fiscal 2025 entry sums to $359,040M against $359,051M — 0.003% apart. After MDT's 147%-of-revenue geography, SPGI's omitted $2,299M segment, HWM losing two segments in consecutive years and TJX and SYK omitting the United States, a segment block that reconciles to the dollar in two consecutive years is a genuinely clean result and is recorded as one. The limitation is different and must be stated: the two years use different segment structures and were NOT recast, so no year-over-year segment comparison is available from the payload. The FY2018 and FY2011 entries additionally use long-obsolete "Distribution Solutions / Technology Solutions" and "Distribution Segment / Technology Segment" labels, and FY2015 through FY2012 report only Medical-Surgical.

inc_q — TESTED for the MO/APP two-basis defect and PASSED. All nine quarters are on the same basis and the four most recent reconcile to earn_cal.revenueActual exactly ($96,295M, $106,158M, $103,150M, $97,827M). No reporting-basis change was found across the fiscal 2026 segment reorganisation or the Norway divestiture, which is the specific failure mode that caught MO across a change in excise-tax presentation and APP across a divestiture. Note however that inc_q Q4 FY2026 reports interestExpense of −$61M, a negative interest expense, which is anomalous and unexplained; the annual figure of $247M is consistent with the other quarters and is used.

earn_cal — TESTED for the SPGI mixed-basis defect and PASSED. All five actual-versus-estimate pairs are on the adjusted-EPS basis, and the FY2026 sum of actuals ($39.15) reconciles to est.epsAvg for the same year ($39.011) within 0.4%. No continuing-operations-versus-total mismatch of the SPGI class was found.

Also checked and recorded: quote.yearHigh/yearLow ($999 / $637) against tech.hi52/lo52 ($995.69 / $659.01) — a 0.3% and 3.4% discrepancy at the low end, the largest in this batch; tech is used throughout for internal consistency, which is the more conservative choice since it shows the stock further above its low. Implied share count (market capitalisation ÷ price = 117.08M) against revenuePerShareTTM (403,430/3,304.095 = 122.10M) differs by 4.1% — the per-share ratios are struck on the weighted-average diluted count of ~122M while the market capitalisation uses the current outstanding count of ~117M, which is consistent with $4.8 billion of repurchase during the year but means per-share ratios and market-capitalisation-derived figures are not on the same share base. effectiveTaxRateTTM of 17.8% is consistent with incomeTaxExpense of $1,102M on incomeBeforeTax of $6,201M (17.8%).

returnOnEquityTTM — source stated. Present in km_ttm at −2.654 and absent from ratios_ttm. Both would be void regardless, for the reason in finding 3.

Non-equity tripwire — checked and passed. MCK is common stock, NYSE-listed. Price of $830.43 is not par-like; beta is 0.315 — notably low and consistent with a defensive distributor; the dividend is variable and small ($3.28, 0.40% yield, 8.0% payout); volume was 805,904 shares (~$669M of turnover); the 52-week band of $659.01 to $995.69 is a 51% range. This is common equity.

9. Technicals

• Price $830.43. −16.6% from the 52-week high of $995.69; +26.0% above the 52-week low of $659.01. Position within the annual range: 51st percentile — almost exactly the midpoint.
• The moving averages have crossed and the price is testing the longer one from beneath: +4.7% above a 50-day average of $792.78 but −0.7% BELOW a 200-day average of $836.29. The stock is sitting essentially ON its 200-day average, which is the most technically informative single fact in this section — a break above it on volume would be the first confirmation the six-month consolidation has ended.
• RSI 58.0 — constructive, not stretched. MACD +16.8, positive.
• Maximum drawdown from peak over the trailing year: −16.6%, a mid-range figure for this batch.
• Relative performance, and it is the substance of the opportunity: 3-month +2.8% against SPY +7.6% and QQQ +7.7%; 6-month −1.9% against SPY +11.1% and QQQ +15.7%; 12-month +18.8% against SPY +24.3% and QQQ +30.8%. This stock has underperformed the S&P by 13 points over six months while growing adjusted earnings 18% and repurchasing 4.9% of itself. That gap is the de-rating that produced the current 18.8x forward multiple, and it is why there is an entry here at all.
• Sentiment: 1 strong buy, 24 buy, 6 hold, 0 sell across 31 analysts; consensus target $1,006 (+21.1%), median $1,050 (+26.4%), high $1,085 (+30.7%), low $875 — 5.4% ABOVE spot. Not one covering analyst has a target below the current price, and not one has a sell rating. We treat that as a caution rather than a comfort: unanimity in a name with 24% single-customer concentration and negative book equity is a crowding marker, and it is a principal reason our $930 sits 7.6% below the consensus.

Today's move and what it does to the entry

MCK closed 2026-08-04 at $830.43, up 0.40% or $3.29 from $827.14. It opened at $815.985, traded $810.88 to $835.95, and closed in the upper half of the range on 805,904 shares. No company-specific filing is dated 2026-08-04; the last event was the 2026-07-24 annual-meeting 8-K.

The honest read: the setup is good and the timing is not. A stock at the midpoint of its annual range, sitting on its 200-day average, with RSI at 58 and a positive MACD, at 18.8x a 13%-growth forward estimate, is a reasonable place to build a position. It is not a reasonable place to build one twenty-four hours before an earnings release, and the verdict below is explicit about that. The correct behaviour is to let the print happen, read the fiscal 2027 outlook against the $44.26 consensus, and act on the result — in either direction.

10. Insiders — eight transactions, all of them the same annual director grant

Eight transactions, one date, one transaction type, one share count, eight directors. This is the annual equity grant made on the day of the 2026-07-22 annual meeting and it contains no information whatsoever.

Three of the eight are recorded as Common Stock at $814.04 rather than as restricted stock units at $0 — the difference between directors who elected immediate stock and those who took RSUs, not between a purchase and a grant. None of the eight is an open-market purchase.

What the file does NOT contain is the informative part. There is not a single transaction by any executive officer in the last eight recorded filings — no purchase and no sale by Brian S. Tyler, by the chief financial officer, or by any segment president. On a company that has just announced the separation of an entire segment, signed a private-equity investor into it and placed $2.25 billion of secured debt, the absence of any officer transaction in either direction is genuinely uninformative rather than mildly negative. We record it as a gap in the evidence, not as a signal.

A note on what the eight-transaction window costs us here. Because all eight slots are consumed by a single day's director grants, this file provides no visibility at all into officer trading before 2026-07-22 — including the period around the 2026-04-20 Apollo Funds announcement and the 2026-06-09 Term B financing, which is exactly when insider behaviour would have been most informative. That is a limitation of the data window and we state it rather than drawing a conclusion from silence.

11. Verdict, kill-criteria and flip conditions

Buy — Tactical. Entry deferred past the 2026-08-05 earnings release.

The arithmetic. At $830.43 McKesson trades at 18.8x the FY2027 consensus of $44.26 and 16.5x FY2028's $50.42, having earned 31.1% on invested capital and 41.6% on capital employed in a fiscal year that grew revenue 12.4%, lifted adjusted EPS to $39.15 and GAAP diluted EPS from $25.72 to $38.38, and repurchased $4.8 billion of stock — 4.9% of the market capitalisation. Our base fair value of $930 is 12.0% above spot with 2.0:1 asymmetry, and the company returns approximately 5.3% a year to shareholders. The expected return decomposes as roughly two-thirds earnings growth and one-third shareholder yield, with essentially nothing required from the multiple.

The entry. The stock is 16.6% below its 52-week high, at the 51st percentile of its annual range, sitting 0.7% below its 200-day average, having underperformed the S&P by 13 points over six months while growing earnings 18%. That is a de-rating rather than a deterioration, and it is the reason there is an opportunity at all.

The unpriced catalyst. Three filings across ten weeks — the 10-K's separation disclosure and risk factor, the 2026-04-20 Apollo Funds agreement for ~13% of Medical-Surgical for ~$1.25 billion, and the 2026-06-09 $2,250 million senior secured Term B loan due 2032 at the subsidiary holdco — describe a segment being capitalised for departure. The vendor payload contains none of it, the segment is only 2.9% of revenue so no screen flags it, and we can find no evidence it is in the price.

Why Tactical and not Core, stated as five specific reservations.

First, and decisively for timing: results are released tomorrow. The fiscal 2027 outlook — which the 10-K explicitly declines to reproduce — is the anchor for the $44.26 consensus on which every fair value here rests. No Core position is established the day before a print, and no Tactical one either. The instruction attached to this verdict is to wait for the number.

Second, the knowledge base is one voice. Three claims, all from a single channel, all bullish, all speaker: null. The concentration test was run and failed at 100%. Removing that voice empties the lane. And the most recent and most specific of the three — that McKesson had re-rated from 11x to 22x on AI-driven margins — has stalled: the stock is down 1.9% over six months and the multiple has fallen to 18.8x forward. Nothing in the 10-K attributes any margin improvement to artificial intelligence.

Third, CVS is 24% of revenue. The top ten customers are 73%. This is the only risk in the file that could remove a quarter of the revenue base in a single event, and the price contains no discount for it.

Fourth, the separation is announced, not executed. The 10-K's own risk factor states it "may not be completed on the currently contemplated terms or timeline, or at all" and lists five outstanding conditions. If Apollo's investment fails regulatory approval, $2.25 billion of secured debt sits at a subsidiary with no exit.

Fifth, book equity is negative $2,172 million. Harmless at $6.2 billion of operating cash flow, and immediately material in any liquidity event. It also renders the vendor's own composite rating (B−/2, with 1-out-of-5 scores on three metrics) actively misleading, which is a reason to be careful about what else in this file is being read mechanically.

Pre-registered KILL criteria — what would take this to Watch or Avoid:

• A fiscal 2027 outlook at tomorrow's print implying adjusted EPS below $42.50, roughly 4% under the current consensus — the fair values in this dive move directly with that number.
• Any disclosure touching the CVS Health relationship — renewal terms, volume shift, or a change in the ~24% concentration.
• The Apollo Funds transaction failing regulatory approval, or the Medical-Surgical separation being deferred without a new date, leaving the $2,250 million secured Term B facility stranded at a subsidiary.
• Adjusted EPS growth below 8% in any two consecutive quarters, which would break the mid-teens compounding the multiple assumes.
• Share repurchase falling below $3 billion annualised, which removes roughly a third of the expected return without any change in the business.
• Opioid or controlled-substance charges returning above $250 million in any fiscal year, or a new state distribution tax of material size.
• A bad-debt event at any customer above 5% of revenue, on the Rite Aid precedent that cost $725 million in fiscal 2024.

Pre-registered UPGRADE conditions — what would take this to Buy — Core:

• A completed Medical-Surgical separation with disclosed proceeds and a stated use of them. That is the single event that would convert an announced intention into realised value.
• Separate revenue AND operating-profit disclosure for Oncology & Multispecialty with growth rates attached. It is $48.4 billion of revenue containing a physician network, 51% of a research organisation and 80% of an ophthalmology platform, and it is currently one line.
• Two more quarters of double-digit adjusted EPS growth with the buyback maintained above $4 billion annualised.
• A second independent voice in the knowledge base. At present the lane is one person, and a Core rating on a 100%-concentrated conviction lane is not available under house policy.
• Any reduction in the CVS concentration below 20% of revenue through growth elsewhere rather than through loss.

Where MCK fits in the Synthos Framework Portfolio. The healthcare sleeve, entering at 1.5% with a 3% target, and not before 2026-08-05. Sizing note, and it is the operative discipline: the correct response to a 2:1 payoff ratio with a binary event twenty-four hours away is a position built after the event, not into it. If the print is good and the stock rises, the base case shrinks and so should the position; if the print is good and the stock does not move, the entry improves; if the print is bad, the kill criteria above decide. Logged as a tracked Synthos call (Buy — Tactical) as of 2026-08-04 at $830.43, with the fair-value anchors, kill criteria, upgrade conditions and the deferred-entry instruction all gradeable.

Single biggest risk: customer concentration. CVS Health was approximately 24% of fiscal 2026 consolidated revenue and 21% of trade receivables; the top ten customers were approximately 73%. That is disclosed in McKesson's own 10-K and it is not hedgeable, not diversifiable and not discounted in a stock where no covering analyst has a target below the current price. The mitigations are real — multi-year contracts, enormous switching costs, only two alternative distributors of scale, and a profit share far below the revenue share — but they are mitigations of severity, not of probability. The Rite Aid bankruptcy cost $725 million against a far smaller customer. The kill criteria above put any CVS disclosure at the top of the list for exactly that reason.

Provenance & disclosures

• Traceability: 3 knowledge-base claims name McKesson out of 51,928 distilled claims (raw hits 3, entity matches 3, used 3, discarded 0; breadth 1, net conviction positive-low). ALL THREE ARE FROM THE SAME CHANNEL, jordi_visser — 2025-03-30 (bullish, conviction 70, skill 2.0, entities MCK and CAH, "McKesson and Cardinal Health trade below market multiple yet keep producing significant price returns"), and two from 2025-11-16 (bullish, conviction 68 and 60, skill 2.0, "McKesson is a beast, up another 50% this year, gone from 11 PE to 22 on profit margins from companies able to use AI" and "expect more names like this as fundamental funds hunt AI-margin beneficiaries"). The concentration sensitivity test was run because one channel exceeds the one-third threshold, and it FAILED at 100% — removing this single voice empties the lane entirely, so the knowledge base offers no independent corroboration on this name. All three carry speaker: null with speaker_role: independent; per the standing finding that speaker_role is unreliable, the tag is not relied on and the claims are judged by content as independent investor commentary, admitted at low weight rather than excluded. Grading: the March 2025 claim has been right; the November 2025 claims have STALLED — the stock is down 1.9% over six months and has de-rated from the 22x described to 18.8x forward. The claims' attribution of margin expansion to artificial intelligence is not supported by the 10-K, which attributes fiscal 2026 segment profit growth to volumes, a $210 million LIFO credit, the absence of prior-year charges and acquisition contributions; where a claim and a filing offer competing explanations, the filing wins. Homograph check on the three-letter ticker: run case-sensitively with word boundaries, zero false positives, nothing discarded. All quotes are verbatim from the stored claim text.
• Data as-of: fundamentals — income statement, balance sheet, cash flow, segment revenue, customer concentration and separation disclosures through fiscal year ended 2026-03-31, from the 10-K filed 2026-05-08; the Term B loan facility from the 8-K filed 2026-06-12; the officer change from the 8-K filed 2026-07-01 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873602 = 2026-08-04T20:00:02Z ($830.43, +0.40%; 50-DMA $792.78; 200-DMA $836.29; RSI 58.0; MACD +16.8) · knowledge-base claims 2026-08-04. McKesson's fiscal year ends 31 March; fiscal 2026 means the year ended 2026-03-31. All figures come from the Synthos vendor data file for MCK or from the SEC filings in the MCK archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-05-08 (fiscal 2026 — the source of the segment structure, customer concentration, capital expenditure split, acquisition amounts, separation disclosures and risk factors); 10-Q filed 2025-11-06 (Q2 fiscal 2026); 10-Q filed 2026-02-04 (Q3 fiscal 2026); 8-K filed 2026-06-12 — the $2,250 million senior secured Term B loan due 2032 at McKesson Medical-Surgical Top Holdings; 8-K filed 2026-07-01 (chief strategy officer transition: Thomas L. Rodgers retiring 2026-08-01, Ramesh Srinivasan appointed); 8-K filed 2026-07-24 (annual meeting voting results). NO file in this archive contains a [TABLE] marker — statement tables were not preserved for this name, verified by grep -c returning zero on all six files. Every filing-sourced figure in this dive is therefore a prose statement in the 10-K's Financial Review or risk factors, and no primary statement line item was independently verified against a preserved table. There is no fourth-quarter or full-year 10-Q, and no filing covering the quarter that is reported tomorrow.
• Where the filings contradicted or corrected the vendor: capital expenditure — the vendor reports fiscal 2026 capitalExpenditure of $436M where the 10-K states "$436 million and $309 million, respectively, in capital expenditures for property, plant, and equipment and capitalized software", a total of $745M and a 41% understatement, while the SAME field for fiscal 2025 correctly reports $859M ($537M + $322M) — so the block is internally inconsistent across consecutive years; free cash flow is corrected from $5,719M to $5,410M and the FCF yield from 6.11% to 5.56%; acquisition spend — the vendor's acquisitionsNet of −$2,586M against the 10-K's "$3.4 billion of net cash payments for acquisitions, including $2.5 billion and $875 million for the acquisitions of the interests in Core Ventures and PRISM Vision"; earnings per share — the vendor's inc_a.eps of 38.55 and 25.86 against the 10-K's "Diluted earnings per common share attributable to McKesson Corporation was $38.38 and $25.72", the vendor figure being the basic measure; geographic exposure — seg_geo's most recent entry (fiscal 2020) implies 16.6% international against the 10-K's "approximately 4% of our consolidated revenues in each of fiscal 2026 and fiscal 2025"; and the entire corporate-action set — the Medical-Surgical separation, the Apollo Funds ~13%/~$1.25 billion convertible preferred agreement of 2026-04-20, the $2,250 million Term B loan of 2026-06-09, the April 2026 replacement of the credit facilities with a new $5.0 billion revolver maturing 2031, and the Norway divestiture, none of which appears in any vendor field. Where vendor and filing AGREED — recorded, including three tests that have failed on other names: seg_prod reconciles to the reported revenue line EXACTLY in fiscal 2026 ($403,430M against $403,430M) and to within 0.003% in fiscal 2025 — a genuinely clean segment block, with the caveat that the two years use different, un-recast structures; inc_q passed the two-basis test (all nine quarters on one basis, four most recent matching earn_cal.revenueActual exactly) despite a segment reorganisation and a divestiture in the period; earn_cal passed the mixed-basis test (all five pairs on the adjusted-EPS basis, summing to $39.15 against est.epsAvg of $39.011); weightedAverageShsOutDil of 124.1M and 128.1M match the 10-K exactly; and effectiveTaxRateTTM of 17.8% reconciles to incomeTaxExpense ÷ incomeBeforeTax.
• Rejected as a class — the negative-equity cascade: total stockholders' equity of −$2,172M at 2026-03-31 makes priceToBookRatioTTM (−46.68x), priceToFairValueTTM (−46.68x), returnOnEquityTTM (−265%), debtToEquityRatioTTM (−3.97x), debtToCapitalRatioTTM (1.337), longTermDebtToCapitalRatioTTM (1.740), financialLeverageRatioTTM (−37.90x), bookValuePerShareTTM (−$6.83), tangibleBookValuePerShareTTM (−$132.92), shareholdersEquityPerShareTTM (−$17.79), grahamNumberTTM (null) and grahamNetNetTTM (−$377.48) arithmetically correct and analytically void. None is used. The vendor composite rating (B− / 2, with 1-out-of-5 on return on equity, debt-to-equity and price-to-book) is a direct artefact of the same fact and is rejected in its entirety for a company earning 31.1% on invested capital. Separately, est.ebitdaAvg and est.ebitAvg are rejected for the fixed-ratio signature — exactly 1.6003% and 1.3499% of revenueAvg in FY2026, FY2027, FY2028 and FY2029 alike.
• enterpriseValueTTM correction: the vendor's $101,864M omits $1,338M of noncontrolling interests arising from the 80% PRISM Vision and 51% Sarah Cannon Research Institute holdings — the SPGI defect class, here a 1.3% understatement. Corrected EV is $103,202M and EV/EBITDA becomes 14.7x rather than 14.52x. NCI grew 252% during fiscal 2026, so the omission is widening. Finance lease obligations of $2,240M ARE correctly included in totalDebt of $8,614M; no lease double-count of the T or TJX class was found.
• Estimate coverage: 9 analysts on both FY2027 and FY2028 adjusted EPS — the anchor for all three fair values, with an FY2027 range of $44.07 to $44.48, a 0.9% spread that indicates the street is modelling company guidance rather than forming independent views; 3 on FY2029; and ONE analyst each on FY2030 ($66.97) and FY2031 ($79.01), both of which are excluded from every conclusion. Revenue coverage is broader (12-13 analysts) and is treated as non-informative for this name, since three of the five recorded quarters missed the revenue estimate — one by 5.0% — while every one beat on earnings.
• Peer note: the vendor peer set is Bristol-Myers Squibb, Cardinal Health, Cencora, CVS Health, GSK, HCA, Medtronic, Sanofi, Stryker and Vertex. Only Cardinal Health and Cencora are drug distributors; four are branded pharmaceutical manufacturers, two are device makers, one is a hospital operator, and one — CVS Health — is McKesson's own largest customer at ~24% of revenue. No peer-multiple comparison is drawn.
• Fair-value caveat: the $700 / $930 / $1,090 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 15.9x the low of $44.07, 21.0x the mean of $44.26, and 24.5x the high of $44.48 — each cross-checked against FY2028 (13.9x, 18.4x, 21.6x). Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 19x gives $841, essentially spot; 23x gives $1,018. Book-value cross-checks are unavailable because book equity is negative, so the multiple work has no balance-sheet anchor — an unusual and stated limitation. The base assumes the multiple essentially holds with a small allowance for the post-separation remainder; that allowance is the one piece of judgment in the number.
• Timing — and it governs the verdict. First-quarter fiscal 2027 results are released 2026-08-05, ONE DAY after this dive, against a consensus of $9.56 adjusted EPS and $103,875M of revenue. Fiscal 2026 results were released 2026-05-07, ninety days before this dive, beating consensus adjusted EPS by 1.1% ($11.69 against $11.56) while missing revenue by 5.0% ($96,295M against $101,346M). The Buy — Tactical rating carries a hard instruction that no position is established before the print, and the fiscal 2027 outlook — which the 10-K explicitly declines to reproduce — is the anchor for the FY2027 consensus on which all three fair values rest. If tomorrow's guidance moves that number materially, this document is superseded. The most recent insider filings are dated 2026-07-23 and are the annual director grant. 2026-08-04 carried no company-specific filing.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.